NEW YORK (GenomeWeb News) – Sigma-Aldrich today said that its BioReliance business has signed an agreement to acquire colonies and cell lines for toxicology testing from Agilent Technologies.

The deal covers colonies required for Agilent's Big Blue transgenic rodent mutation assay, which are in vivo genetic toxicology assays that measure mutation frequency in tissue. BioReliance will now own the Big Blue mutation models and will be the exclusive supplier of testing services based on the model.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.